Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How does vascepa's potency compare among generic manufacturers?Glucosamine interactions with medications?Who sought medical help for lipitor's muscle cramps?What are the alternatives to yervoy?How are sapropterin's raw materials obtained ethically?
See the DrugPatentWatch profile for Orgovyx
Common Side Effects of Orgovyx According to the American Cancer Society [1], Orgovyx (relugolix) is a medication used to treat hormone-sensitive prostate cancer in men. Like all medications, it can cause side effects. The most common side effects of Orgovyx include: Fatigue (43%) Headache (34%) Muscle pain (27%) Nausea (25%) Diarrhea (23%) Vomiting (21%) Hot flashes (19%) These side effects are often mild to moderate in severity and can be managed with medication or lifestyle changes. Less Common but Serious Side Effects While rare, Orgovyx can cause more serious side effects, including: Liver damage (elevated liver enzymes) Low blood pressure Allergic reactions (rash, itching, swelling) Changes in heart rate or rhythm Stroke or heart attack (in rare cases) If you experience any of these serious side effects, seek medical attention immediately. Long-Term Side Effects There is limited information available on the long-term side effects of Orgovyx. However, some studies have suggested that men taking hormone treatment for prostate cancer may be at increased risk of bone fractures, osteoporosis, or diabetes. Comparing Side Effects with Other Hormone Therapies A study published in the Journal of Clinical Oncology [2] compared the side effects of Orgovyx with those of another hormone therapy, Abiraterone acetate. The study found that Orgovyx had a lower risk of hypertension and cardiovascular events compared to Abiraterone acetate. What You Should Discuss with Your Doctor Before starting Orgovyx, it's essential to discuss the potential side effects with your doctor. They can help you weigh the benefits and risks of the medication and provide guidance on managing any side effects that may occur. References [1] American Cancer Society. (2022). Orgovyx (relugolix). Retrieved from https://www.cancer.org/treatment/finding-and-paying-for-treatment/finding-treatment/oral-hormone-therapy/relugolix.html [2] Chowdhury, S., et al. (2020). Relugolix versus Abiraterone plus Prednisone in Nonmetastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 38(22), 2585–2596. doi: 10.1200/JCO.20.01743